PROCEPT BioRobotics (PRCT) Common Equity (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Common Equity data on file, last reported at $347.7 million in Q1 2026.

• Quarterly Common Equity fell 10.66% year-over-year to $347.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $347.7 million (down 10.66% YoY) and the FY2025 annual result came in at $365.9 million, down 9.04% from the prior year.
• Common Equity eased to $347.7 million in Q1 2026 per PRCT's latest filing, from $365.9 million in the prior quarter.
• Across five years, Common Equity topped out at $402.2 million in Q4 2024 and bottomed at $155.9 million in Q2 2023.
• The 5-year median for Common Equity is $264.0 million (2024), against an average of $285.1 million.
• The widest annual swing landed in 2022, when Common Equity soared 230.38%; it then tumbled 34.82% in 2023.
• Tracing PRCT's Common Equity over 5 years: stood at $197.1 million in 2022, then soared by 42.46% to $280.8 million in 2023, then jumped by 43.27% to $402.2 million in 2024, then slipped by 9.04% to $365.9 million in 2025, then retreated by 4.98% to $347.7 million in 2026.
• Per Business Quant, the three latest PRCT Common Equity figures stand at $347.7 million (Q1 2026), $365.9 million (Q4 2025), and $380.3 million (Q3 2025).

Peer Comparison